Understand the source comparison
Best Peptides for BPH Prostate: Comparison
BPC-157 Inhibits NF-κB inflammatory pathway; promotes vascular repair Strong. Multiple tissue injury models show reduced inflammation and accelerated healing 250–500 mcg subcutaneous daily Minimal adverse effects reported; no human safety trials Best mechanist
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Inhibits NF-κB inflammatory pathway; promotes vascular repair
- Strong. Multiple tissue injury models show reduced inflammation and accelerated healing
- 250–500 mcg subcutaneous daily
- Minimal adverse effects reported; no human safety trials
- Best mechanistic support for inflammation reduction. No human prostate trials
- Thymosin Beta-4
- Blocks TGF-β-driven fibrosis; modulates extracellular matrix remodeling
- Moderate. Rat BPH models show 28% prostate weight reduction
- 5–10 mg subcutaneous 2x weekly
- Generally well-tolerated in wound healing studies; injection site reactions possible
- Strong anti-fibrotic rationale. Human prostate data absent
- Epitalon
- Extends cellular lifespan; reduces senescence-associated inflammation
- Weak. Small Russian studies claim PSA normalization; mechanism plausible but data limited
- 5–10 mg subcutaneous for 10-day cycles
- Minimal reported adverse effects; limited Western validation
- Mechanistic appeal for aging-related BPH. Clinical proof lacking